scholarly journals The impact of hyperbaric oxygen therapy on late radiation toxicity and quality of life in breast cancer patients

2021 ◽  
Author(s):  
Marilot C. T. Batenburg ◽  
Wies Maarse ◽  
Femke van der Leij ◽  
Inge O. Baas ◽  
Onno Boonstra ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Side Effects ◽  
Cancer Patients ◽  
Oxygen Therapy ◽  
Radiation Toxicity ◽  
Breast Pain ◽  
Breast Cancer Patients

Abstract Purpose To evaluate symptoms of late radiation toxicity, side effects, and quality of life in breast cancer patients treated with hyperbaric oxygen therapy (HBOT). Methods For this cohort study breast cancer patients treated with HBOT in 5 Dutch facilities were eligible for inclusion. Breast cancer patients with late radiation toxicity treated with ≥ 20 HBOT sessions from 2015 to 2019 were included. Breast and arm symptoms, pain, and quality of life were assessed by means of the EORTC QLQ-C30 and -BR23 before, immediately after, and 3 months after HBOT on a scale of 0–100. Determinants associated with persistent breast pain after HBOT were assessed. Results 1005/1280 patients were included for analysis. Pain scores decreased significantly from 43.4 before HBOT to 29.7 after 3 months (p < 0.001). Breast symptoms decreased significantly from 44.6 at baseline to 28.9 at 3 months follow-up (p < 0.001) and arm symptoms decreased significantly from 38.2 at baseline to 27.4 at 3 months follow-up (p < 0.001). All quality of life domains improved at the end of HBOT and after 3 months follow-up in comparison to baseline scores. Most prevalent side effects of HBOT were myopia (any grade, n = 576, 57.3%) and mild barotrauma (n = 179, 17.8%). Moderate/severe side effects were reported in 3.2% (n = 32) of the patients. Active smoking during HBOT and shorter time (i.e., median 17.5 vs. 22.0 months) since radiotherapy were associated with persistent breast pain after HBOT. Conclusion Breast cancer patients with late radiation toxicity reported reduced pain, breast and arm symptoms, and improved quality of life following treatment with HBOT.

scholarly journals Prospective Feasibility Study of A Mindfulness-Based Program for Breast Cancer Patients in the Southeastern US

2021 ◽  
Author(s):  
Carolina Salvador ◽  
Phyllis Mark ◽  
Teri Hoenemeyer ◽  
Victoria McDonald
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Cancer Patients ◽  
Feasibility Study ◽  
Program Effectiveness ◽  
Breast Cancer Patients ◽  
Mindfulness Skills ◽  
Success Criteria

Abstract Background: Mindfulness interventions are effective at improving psychological distress and quality of life in cancer patients. Few mindfulness programs for cancer recovery exist in major cities throughout the Southeastern United States. The primary objective of this study was to assess the feasibility of a modified mindfulness-based stress reduction (MBSR) program for breast cancer patients in Birmingham, Alabama. The secondary objective was to estimate the effectiveness of the modified program by examining changes in patients’ mindfulness skills and quality of life. Methods: This study was a prospective, quasi-experimental feasibility study conducted over 10 months within a university hospital in Birmingham, Alabama. Feasibility was achieved if 80% of eligible patients screened chose to enroll in the study and 70% of enrolled patients attended all 8 program sessions. Program effectiveness was estimated by changes in mindfulness and quality of life indicators. These indicators were measured by validated scales administered at pretest, posttest, and 8-week follow-up and assessed with a non-parametric Friedman test. The program curriculum followed a modified version of Dr. Jon Kabat-Zinn’s MBSR program. Program sessions included sitting meditation, hatha/restorative yoga, and a body-focused attention practice called body scan. There were 3 groups of 2-5 patients.Results: The sample consisted of 12 patients. Forty-four percent (12/27) of eligible patients enrolled in the study, failing to meet recruitment success criteria of 80%; two out of 12 enrolled patients completed all 8 program sessions, resulting in 16.7% (2/12) retention, which fell below the retention success criteria of 70%. However, more than half (66.7%) of participants completed at least 7 sessions. Between baseline and 8-week follow-up, patients demonstrated statistically significant improvements in distress, general wellbeing, and fatigue-related quality of life.Conclusions: Feasibility objectives were not achieved. However, a large majority of participants (66.7%) completed 7 of the 8 program sessions. Program effectiveness was promising for distress, fatigue, and wellbeing. Results warrant further research on MBSR programs for breast cancer patients in Alabama. Future programs should investigate how to increase overall recruitment numbers, focusing on introducing mindfulness concepts to inexperienced populations. Studies should consider hosting sessions in community locations or via telemedicine to improve accessibility.

scholarly journals Evaluation of Drug Side Effects Chemotherapy on Quality of Life (QOL) Breast Cancer Patients at Hospital X in Jakarta

2019 ◽  
Vol 17 (1) ◽  
pp. 9
Author(s):  
Sondang Khairani ◽  
Sesilia A Keban ◽  
Meyke Afrianty
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Side Effects ◽  
Cancer Patients ◽  
Sampling Technique ◽  
Cancer Type ◽  
Drug Side Effects ◽  
Breast Cancer Patients ◽  
Chemotherapy Drugs

Breast cancer is the number one cancer type discovered at women in the world. Most causes are genetic factors and hormonal factors. One cancer treatments with chemotherapy. Chemotherapy drugs active in cells dividing and reproducing, but cells normally to be affected by chemotherapy and side effects from chemotherapy drugs affect quality of life. The aim of the study to evaluate side effects of chemotherapy drugs on the quality of life of breast cancer patients. Sampling technique observational prospective breast cancer patients with completed the chemotherapy cycle from September 2017 to April 2018 with descriptive analysis and statistics by looking correlation between drug side effects and Quality of Life (QoL). Results of the study were side effects of fatigue 100%, nausea 67,5%, vomiting 60%, no appetite 63,75%, fever 42,5%, joint pain 43,75%, diarrhea 16,25%, difficulty swallowing 16,25%, allergies 5%, itching 1,25%, mouth sores 3,75%, swollen right hand 1,25%, constipation 3,75%. QoL results are physical 6,2%; psychology 5,3%; social 4,9%; spiritual 6,8%. Results of Sperman test showed no correlation between the side effects of chemotherapy and QoL P> 0,05. This study shows that there is no relationship between the side effects drug chemotherapy and QoL in breast cancer patients.

A randomized controlled trial (RCT) of long-term follow-up for early stage breast cancer comparing family physician to specialist care: A report of secondary outcomes

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 6003-6003
Author(s):  
E. Grunfeld ◽  
J. Julian ◽  
M. Levine ◽  
K. Pritchard ◽  
D. Coyle ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Patient Satisfaction ◽  
Cancer Patients ◽  
Family Physician ◽  
Early Stage ◽  
Breast Cancer Patients ◽  
Secondary Outcomes

6003 Background: Breast cancer patients usually receive follow-up in specialist cancer clinics. We have reported that family physician follow-up of breast cancer patients is a safe and acceptable alternative to specialist follow-up as measured by the primary clinical outcome of the rate of serious clinical events (Grunfeld et al, JCO 2006;24(6)). We report here the secondary outcomes of this trial: quality of life domains, patient satisfaction and patients’ costs. Methods: Women with early stage breast cancer who had completed adjuvant therapy (patients may have continued on adjuvant hormonal therapy), who were disease free and between 9 and 15 months after diagnosis, were allocated to receive follow-up in a cancer clinic according to usual practice (CC arm) or follow-up from their own family physician (FP arm). For patients without recurrence, quality of life (QL) measured by the SF36, patient satisfaction, and patients’ costs were measured every 6 months. For patients with recurrence QL measured by the EORTC QLQ C-30 was measured at the time of recurrence. Results: 483 patients were allocated to the FP arm and 485 to the CC arm. Median follow-up was 3.5 years. There were no significant differences between groups on change scores for SF36 subscales to 24 months, or EORTC functional subscale scores at the time of recurrence. Patients’ costs of follow-up (travel costs, out-of-pocket expenses, and lost earnings) were significantly less to 24 months (p < 0.02) in the FP arm. Although costs were less between 36 and 48 months, these were not significant. Conclusions: Family physician follow-up of breast cancer patients does not have a negative impact on clinical or QL outcomes and is less costly for patients. No significant financial relationships to disclose.

scholarly journals The Chinese herb Xiaoaiping protects against breast cancer chemotherapy-induced alopecia and other side effects: a randomized controlled trial

2019 ◽  
Vol 47 (6) ◽  
pp. 2607-2614 ◽  
Author(s):  
Fujie Yu ◽  
Yuanmei Li ◽  
Jiaqun Zou ◽  
Lisha Jiang ◽  
Chun Wang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Side Effects ◽  
Cancer Patients ◽  
Chinese Herb ◽  
Nausea And Vomiting ◽  
Control Group ◽  
Breast Cancer Patients ◽  
Wbc Count

Objective To investigate the effects of the Chinese herbal medicine Xiaoaiping to treat chemotherapy-induced side effects in breast cancer patients. Methods Ninety-three adult patients who attended our hospital and met the entry criteria from January 2016 to December 2017 were included. Patients were randomly divided into the control group (routine chemotherapy only) and the combined group (routine chemotherapy and Xiaoaiping). Demographic data and clinical variables were collected, and side effects including alopecia, nausea and vomiting, diarrhea, white blood cell (WBC) count, aspartate aminotransferase (AST) levels, and the quality of life were evaluated. Results Basic clinical characteristics were not different between the groups. There were significantly fewer patients with alopecia grade 3–4, but significantly more patients with alopecia grade 1–2, in the combined group compared with the control group. Disease-free time for alopecia was longer in the combined compared with the control group. Overall, the side effects were significantly more serious in the control compared with the combined group. Patients in the combined group had better quality of life than the control patients. Conclusion Xiaoaiping can improve alopecia, nausea and vomiting, and diarrhea symptoms, WBC count, AST levels, and the quality of life in breast cancer patients.

Sign in / Sign up

Export Citation Format

Share Document